Systems Approaches to Treatment Response to Imatinib in Severe Asthma: A Pilot Study

There is an acute need for advances in pharmacologic therapies and a better understanding of novel drug targets for severe asthma. Imatinib, a tyrosine kinase inhibitor, has been shown to improve forced expiratory volume in 1 s (FEV(1)) in a clinical trial of patients with severe asthma. In a pilot...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Seung Han, Foer, Dinah, Cahill, Katherine N., Israel, Elliot, Maiorino, Enrico, Röhl, Annika, Boyce, Joshua A., Weiss, Scott T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064376/
https://www.ncbi.nlm.nih.gov/pubmed/33805900
http://dx.doi.org/10.3390/jpm11040240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064376/
https://www.ncbi.nlm.nih.gov/pubmed/33805900
http://dx.doi.org/10.3390/jpm11040240

Ejemplares similares